Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
ConditionMood Disturbance
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-50
SponsorAuburn University
About this trial
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are:
Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo.
Participants will consume an 8-week supplement of both:
* 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Eligibility criteria
Qualifiers
Adults age 18-50
Depression subscale score of >9/21 on the DASS-21
No change in medications or supplements over the past 3 months
Can read and speak English
Disqualifiers
Currently consume curcumin or green tea daily
Currently, pregnant, nursing, or trying to become pregnant
Currently diagnosed with a perimenopausal disorder
Trial design
Treatments tested in this trial
- Curcumin
- Epigallocatechin Gallate
- Placebo
Treatment groups
64 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov